Exploring the diagnostics market for simple and fast point of care antibody dete...
Exploring the diagnostics market for simple and fast point of care antibody detection
Antibody detection assays are used in many fields of biomedicine including the diagnosis of infectious diseases, autoimmune diseases and allergies. Current analytical techniques for antibody detection come with intrinsic limitatio...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
IMMUNO-MONITORING
ELECTROCHEMICAL DNA-BASED SENSORS FOR IMMUNOTHERAPY MONITORI...
150K€
Cerrado
PTQ-10-04064
Desarrollo metodológico basado en técnicas moleculares y pro...
69K€
Cerrado
LUMABS
Therapeutic antibody drug monitoring using bioluminescent se...
150K€
Cerrado
RAPP-ID
Development of RApid Point of Care test Platforms for Infect...
16M€
Cerrado
MULTIPOC
Highly Multiplexed Affinity Proteomics for Point of Care Dia...
2M€
Cerrado
TopSpec
Next generation precision antibody profiling from science...
4M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Antibody detection assays are used in many fields of biomedicine including the diagnosis of infectious diseases, autoimmune diseases and allergies. Current analytical techniques for antibody detection come with intrinsic limitations such as the requirement for multiple time-consuming incubation steps, multiple reagents, and/or sophisticated equipment. Supported by an ERC consolidator grant we have developed a highly modular sensor concept for antibody-responsive reporter enzymes (AbSens) that addresses many of these challenges. Key advantages include the ability to monitor antibodies directly in solution, easy read-out based on a simple color reaction, adaptability to target any antibody of interest, and high affinity and specificity. We believe that this generic sensor platform could find applications in low-cost point-of-care diagnostics, clinical research, and the development of therapeutic antibodies.
The goal of AbSens is to identify those opportunities in the huge market of antibody-based diagnostics where our sensor platform provides unique advantages over existing technologies, both in terms of analytical performance and economics.
To enable the next step towards commercialization, the analytical performance of our technology will be compared to current gold standards using relevant clinical samples in collaboration with commercial parties and clinicians. Other commercially important parameters are the long-term stability of the assay components and the development of a yeast-based production system to lower the cost of enzyme production. Based on an in-depth market analysis and the feedback we receive from external stakeholders on the performance of our technology, a realistic strategy will be developed for the further commercialization. In anticipation of exploring the commercialization of our AbSens technology we filed a US provisional patent application in Sept. 2012 on the key underlying technology, which was recently continued via the PCT route.